LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516433-13-00

Acronym

21-PP-23

Enrollment

Registered

2024-09-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progressive multiple sclerosis

None listed

Sex/Gender

All

Age

18 Years to 64 Years

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026